Skip to Content
MilliporeSigma

A3230

AR-A014418

≥98% (HPLC), solid

Synonym(s):

N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

5 MG

$227.00

25 MG

$774.00

$227.00

Available to ship TODAYDetails

Request a Bulk Order

About This Item

Empirical Formula (Hill Notation):
C12H12N4O4S
CAS Number:
487021-52-3
Molecular Weight:
308.31
NACRES:
NA.77
PubChem Substance ID:
329770820
UNSPSC Code:
12352200
MDL number:
MFCD08277040
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

AR-A014418, ≥98% (HPLC), solid

InChI

1S/C12H12N4O4S/c1-20-9-4-2-8(3-5-9)6-13-11(17)15-12-14-7-10(21-12)16(18)19/h2-5,7H,6H2,1H3,(H2,13,14,15,17)

SMILES string

COc1ccc(CNC(=O)Nc2ncc(s2)[N+]([O-])=O)cc1

InChI key

YAEMHJKFIIIULI-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

solid

color

off-white to tan

solubility

DMSO: ≥20 mg/mL, clear, light yellow
H2O: insoluble

originator

AstraZeneca

storage temp.

2-8°C

Quality Level

100

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
G5547D1944SML0360
AR-A014418 ≥98% (HPLC), solid

Sigma-Aldrich

A3230

AR-A014418

GSK837149A ≥98% (HPLC), solid

Sigma-Aldrich

G5547

GSK837149A

D4476 ≥98% (HPLC), solid

Sigma-Aldrich

D1944

D4476

TAK-715 ≥98% (HPLC)

Sigma-Aldrich

SML0360

TAK-715

form

solid

form

solid

form

solid

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥20 mg/mL, clear, light yellow, H2O: insoluble

solubility

DMSO: >10 mg/mL, H2O: insoluble

solubility

DMSO: ~20 mg/mL, H2O: insoluble

solubility

DMSO: >15 mg/mL

originator

AstraZeneca

originator

GlaxoSmithKline

originator

GlaxoSmithKline

originator

-

Application

AR-A014418 has been used as an inhibitor of glycogen synthase kinase 3 (GSK3).[1]

Biochem/physiol Actions

AR-A014418 is a glycogen synthase kinase 3 (GSK3) inhibitor.
Glycogen synthase kinase 3 (GSK3) is a serine/threonine kinase that has been implicated in pathological conditions such as diabetes and Alzheimer′s disease. GSK3 inhibitor, AR-A014418, inhibits GSK3 (IC50 = 104 nM), in an ATP-competitive manner (Ki = 38 nM). AR-A014418 does not significantly inhibit cdk2 or cdk5 (IC50 > 100 μM) or 26 other kinases, demonstrating high specificity for GSK3.

Features and Benefits

This compound is featured on the PKB/Akt page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

AR-A014418 may have chronic pain-relieving properties. In mice having neuropathic pain, this molecule has been shown to have antihyperalgesic effects. AR-A014418 may modulate proinflammatory cytokines and the catecholaminergic and serotonergic pathways.[2] It has also been studied that AR-A014418 inhibits growth of pancreatic cancer cells.[3]

Storage Class

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000164383
0000164384
0000164384
0000164383
0000120164

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Po-Hung Hsu et al.
Scientific reports, 8(1), 12882-12882 (2018-08-29)
Alzheimer's disease (AD) is a neurodegenerative disease that is the leading cause of age-related dementia. Currently, therapeutic agent delivery to the CNS is a valued approach for AD therapy. Unfortunately, the CNS penetration is greatly hampered by the blood-brain barrier
Miyuki Yoshiya et al.
Frontiers in neural circuits, 7, 191-191 (2013-12-19)
Modulation of synapses under acute stress is attracting much attention. Exposure to acute stress induces corticosterone (CORT) secretion from the adrenal cortex, resulting in rapid increase of CORT levels in plasma and the hippocampus. We tried to test whether rapid
Shadi Mamaghani et al.
PloS one, 7(7), e41102-e41102 (2012-07-26)
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) induces apoptosis in a variety of cancer cell lines with little or no effect on normal cells. However, its effect is limited as some cancers including pancreatic cancer show de novo resistance to
Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action
Mazzardo-Martins L, et al.
Neuroscience, 226, 411-420 (2012)
Huilan Xie et al.
Journal of dental sciences, 17(2), 802-810 (2022-06-28)
Glycogen synthase kinase-3β (GSK3β) inhibitor enhances bone formation, while dental pulp stem cells (DPSC) are potentially used to repair bone defects. The present study aimed to investigate the effect of AR-A014418 (AR, a specific glycogen synthase kinase-3β inhibitor) on the
View All Related Papers

Articles

Cancer Stem Cells: Targets for Cancer Therapy

Cancer stem cell media, spheroid plates and cancer stem cell markers to culture and characterize CSC populations.

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service